StemCell Therapy

“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.

“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”

“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”

“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.

"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/6WeU6kIIs6E/bluebird-and-banking-media-pluses-for.html

“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University) says initial estimates for the treatment run around ¥50
million ($512,000) per person."

“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/IObtHBtAe_E/cost-of-stem-cell-therapy-estimated.html

On 18 June 2013, there was an announcement at the Princess Margaret Cancer Centre, Toronto. There was also a post on the California stem cell agency blog entitled: Clinical trial to thwart cancer stem cells may begin soon. An excerpt from the post:

The Prince Margaret Center announced the FDA filing, called an Investigational New Drug application (IND), at an event in Toronto recognizing the private donors. A press release about the announcement was picked up at this biotech news site.

The Principal Investigators present for the announcement were Dr. Tak Mak of the Princess Margaret Cancer Centre and Dr. Dennis Slamon of the University of California, Los Angeles (UCLA). What they have done is summarized in another excerpt from the blog post:

By working first to understand the various proteins that drive cells to divide, particularly in cancer, they were able to pinpoint an enzyme, that if blocked, could be the key to keeping cancer in check. They then discovered that this enzyme, called PLK4, can be derailed by a new drug they developed. In the lab, it has been shown to inhibit the growth of breast, ovarian, colorectal, lung, pancreatic and prostate cancer, as well as melanoma.

Information about the human PLK4 protein is available here.

Some background: In June 2008, it was announced that a partnership had been formed between Canada’s Cancer Stem Cell Consortium (CSCC) and the California Institute for Regenerative Medicine (CIRM) for international collaboration to advance cancer stem cell research. An excerpt from the CSCC's announcement:

It is proposed that one of the first initiatives to be launched by the CSCC will be a collaboration between Canadian and Californian scientists through CIRM's upcoming Disease Team Research Awards Competition, which will support multi-disciplinary teams of scientists in pursuit of therapies for specific diseases.The goal is to fund teams that will develop therapy or diagnostics for a particular disease or serious injury.Successful proposals will likely include a description of a path to an Investigational New Drug filing at the end of the four-to-five year grant.

Note the intent to file an IND by the end of the term of the grant.

The results of the Disease Team Research Awards Competition were announced on October 28, 2009. The award to Drs. Slamon and Mak is Grant number DR1-01477. See: Therapeutic Opportunities to Target Tumor Initiating Cells in Solid Tumors. As was stated in a page about Cancer Stem Cells on the website of the Canadian Institutes for Health Research (CIHR), this award was to one of two multi-disciplinary research teams co-led by Canadian and Californian scientists. The other team is co-led by Dr. John Dick of the University Health Network and Dr. Dennis Carson of the University of California, San Diego. My blog post (October 29, 2009) about the awards is entitled: Disease Team awards announced. The post ends with this Disclosure:

I'm a member of the Board of the CSCC, but also a staff member (emeritus) at the University Health Network. So, I was in conflict of interest, and was absent during all of the discussions, by the CSCC Board, about which Canadian applications should be considered for the Disease Team awards.

Source:
http://cancerstemcellnews.blogspot.com/2013/06/international-team-submits-ind.html

Assemblywoman Susan Bonilla Photo Source -- Bonilla's office

“After all, aren't we past the days
when we treat women like they are less capable than men of making
sound decisions for their own well-being? It's my body and my choice
if I want to donate a dozen of my eggs to science. Who knows -- maybe
it's my egg that will be used to find a cure for cancer.”

“That sperm-egg parity argument is so
bogus. When men donate sperm, they risk second thoughts about
unknown, random offspring, but they do not risk serious medical side
effects. Egg donation, on the other hand, can be hazardous to your
health. The New York Times reports, "Egg donors can suffer
serious side effects from the powerful hormones needed to generate
multiple eggs." And: "The most significant risk is ovarian
hyper-stimulation syndrome, which can cause bloating, abdominal pain
and, rarely, blood clots, kidney failure and other life-threatening
ailments."

“In practical terms, the bill would
bump up payments from hundreds to thousands of dollars. In Oregon —
which, like most states, does not have regulations governing egg
donation — women recently received $3,000–7,000 each for eggs
used in a study that created stem-cell
lines from cloned human embryos.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/O3i-n3NxdnA/pay-for-eggs-legislation-draws-more.html

On 18 June 2013, there was an announcement at the Princess Margaret Cancer Centre, Toronto. There was also a post on the California stem cell agency blog entitled: Clinical trial to thwart cancer stem cells may begin soon. An excerpt from the post:

The Prince Margaret Center announced the FDA filing, called an Investigational New Drug application (IND), at an event in Toronto recognizing the private donors. A press release about the announcement was picked up at this biotech news site.

The Principal Investigators present for the announcement were Dr. Tak Mak of the Princess Margaret Cancer Centre and Dr. Dennis Slamon of the University of California, Los Angeles (UCLA). What they have done is summarized in another excerpt from the blog post:

By working first to understand the various proteins that drive cells to divide, particularly in cancer, they were able to pinpoint an enzyme, that if blocked, could be the key to keeping cancer in check. They then discovered that this enzyme, called PLK4, can be derailed by a new drug they developed. In the lab, it has been shown to inhibit the growth of breast, ovarian, colorectal, lung, pancreatic and prostate cancer, as well as melanoma.

Information about the human PLK4 protein is available here.

Some background: In June 2008, it was announced that a partnership had been formed between Canada’s Cancer Stem Cell Consortium (CSCC) and the California Institute for Regenerative Medicine (CIRM) for international collaboration to advance cancer stem cell research. An excerpt from the CSCC's announcement:

It is proposed that one of the first initiatives to be launched by the CSCC will be a collaboration between Canadian and Californian scientists through CIRM's upcoming Disease Team Research Awards Competition, which will support multi-disciplinary teams of scientists in pursuit of therapies for specific diseases.The goal is to fund teams that will develop therapy or diagnostics for a particular disease or serious injury.Successful proposals will likely include a description of a path to an Investigational New Drug filing at the end of the four-to-five year grant.

Note the intent to file an IND by the end of the term of the grant.

The results of the Disease Team Research Awards Competition were announced on October 28, 2009. The award to Drs. Slamon and Mak is Grant number DR1-01477. See: Therapeutic Opportunities to Target Tumor Initiating Cells in Solid Tumors. As was stated in a page about Cancer Stem Cells on the website of the Canadian Institutes for Health Research (CIHR), this award was to one of two multi-disciplinary research teams co-led by Canadian and Californian scientists. The other team is co-led by Dr. John Dick of the University Health Network and Dr. Dennis Carson of the University of California, San Diego. My blog post (October 29, 2009) about the awards is entitled: Disease Team awards announced. The post ends with this Disclosure:

I'm a member of the Board of the CSCC, but also a staff member (emeritus) at the University Health Network. So, I was in conflict of interest, and was absent during all of the discussions, by the CSCC Board, about which Canadian applications should be considered for the Disease Team awards.

Source:
http://cancerstemcellnews.blogspot.com/2013/06/international-team-submits-ind.html

Assemblywoman Susan Bonilla Photo Source -- Bonilla's office

“After all, aren't we past the days
when we treat women like they are less capable than men of making
sound decisions for their own well-being? It's my body and my choice
if I want to donate a dozen of my eggs to science. Who knows -- maybe
it's my egg that will be used to find a cure for cancer.”

“That sperm-egg parity argument is so
bogus. When men donate sperm, they risk second thoughts about
unknown, random offspring, but they do not risk serious medical side
effects. Egg donation, on the other hand, can be hazardous to your
health. The New York Times reports, "Egg donors can suffer
serious side effects from the powerful hormones needed to generate
multiple eggs." And: "The most significant risk is ovarian
hyper-stimulation syndrome, which can cause bloating, abdominal pain
and, rarely, blood clots, kidney failure and other life-threatening
ailments."

“In practical terms, the bill would
bump up payments from hundreds to thousands of dollars. In Oregon —
which, like most states, does not have regulations governing egg
donation — women recently received $3,000–7,000 each for eggs
used in a study that created stem-cell
lines from cloned human embryos.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/O3i-n3NxdnA/pay-for-eggs-legislation-draws-more.html

American Health Journal PBS Special Laminine Stem Cell Therapy Full Version
http://www.LaminiNHealth.com/dc/ Doctors are interviewed about Fibroblast Growth Factor, Laminin, Cortisol, Serotonin Do-It-Yourself Stem Cell Therapy - La...

By: David Dolores

More here:
American Health Journal PBS Special Laminine Stem Cell Therapy Full Version - Video

“This bill seeks to create equity in
the field of medical research compensation by removing the
prohibition on compensation for women participating in oocyte (egg)
donation for medical research. All other research subjects are
compensated for their time, trouble, and inconvenience involved in
participating in research. AB 926 ensures that women are treated
equally to all other research subjects - allowing them to actively
evaluate their participation in research studies. Unfortunately, the
ban on compensation has had serious unintended consequences. It has
led to a de facto prohibition on women’s reproductive research in
California, adversely impacting the same women that the ban intended
to protect. With few oocytes donated, fertility research and
fertility preservation research has been at a standstill. This
greatly affects women suffering from fertility issues and women
facing cancer who would like to preserve their oocytes.”

“Egg harvesting exposes healthy young
women to multiple synthetic hormones in order to produce many times
the normal number of eggs per cycle. One of the potential harms is
OHSS, which has resulted in hospitalizations and at least a few
documented deaths. These groups state that many experts remain
concerned about the long-term risks of these drugs, especially
their potential impact on infertility and various cancers.
Follow-up research on egg providers, which could establish the
frequency and severity of these adverse outcomes, is widely
recognized to be grossly inadequate.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SVuriAz87l0/compensation-for-human-eggs-approved-by.html

“Furthermore, as a premier
legislative advocacy and (Nielsen's italics) ballot measure
law ?rm, Nielsen Merksamer can actively and effectively assist CIRM
as it contemplates returning to the voters for additional funding.”

“Another unique advantage offered by
Nielsen Merksamer is that, unlike the vast majority of lobbying ?rms,
since we are a full-service law ?rm, our relationships with our
clients are subject to the attorney-client privilege.”

“(N)o one understands CIRM’s 'total
picture' better than Nielsen Merksamer. Not only has Nielsen
Merksamer been representing CIRM before the Legislature for the past
decade, but Nielsen Merksamer was also one of the principal drafters
of the aforementioned Proposition 71—which brought CIRM to life.
The depth of Nielsen Merksamer’s familiarity with, and
understanding of, CIRM’s mission and structure, the challenges it
faces, and the promise it holds simply cannot be matched by any other
legislative advocate.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/kTRN6kUuSDk/merksamer-makes-only-bid-for-stem-cell.html

“Furthermore, as a premier
legislative advocacy and (Nielsen's italics) ballot measure
law ?rm, Nielsen Merksamer can actively and effectively assist CIRM
as it contemplates returning to the voters for additional funding.”

“Another unique advantage offered by
Nielsen Merksamer is that, unlike the vast majority of lobbying ?rms,
since we are a full-service law ?rm, our relationships with our
clients are subject to the attorney-client privilege.”

“(N)o one understands CIRM’s 'total
picture' better than Nielsen Merksamer. Not only has Nielsen
Merksamer been representing CIRM before the Legislature for the past
decade, but Nielsen Merksamer was also one of the principal drafters
of the aforementioned Proposition 71—which brought CIRM to life.
The depth of Nielsen Merksamer’s familiarity with, and
understanding of, CIRM’s mission and structure, the challenges it
faces, and the promise it holds simply cannot be matched by any other
legislative advocate.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/kTRN6kUuSDk/merksamer-makes-only-bid-for-stem-cell.html

“This bill seeks to create equity in
the field of medical research compensation by removing the
prohibition on compensation for women participating in oocyte (egg)
donation for medical research. All other research subjects are
compensated for their time, trouble, and inconvenience involved in
participating in research. AB 926 ensures that women are treated
equally to all other research subjects - allowing them to actively
evaluate their participation in research studies. Unfortunately, the
ban on compensation has had serious unintended consequences. It has
led to a de facto prohibition on women’s reproductive research in
California, adversely impacting the same women that the ban intended
to protect. With few oocytes donated, fertility research and
fertility preservation research has been at a standstill. This
greatly affects women suffering from fertility issues and women
facing cancer who would like to preserve their oocytes.”

“Egg harvesting exposes healthy young
women to multiple synthetic hormones in order to produce many times
the normal number of eggs per cycle. One of the potential harms is
OHSS, which has resulted in hospitalizations and at least a few
documented deaths. These groups state that many experts remain
concerned about the long-term risks of these drugs, especially
their potential impact on infertility and various cancers.
Follow-up research on egg providers, which could establish the
frequency and severity of these adverse outcomes, is widely
recognized to be grossly inadequate.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SVuriAz87l0/compensation-for-human-eggs-approved-by.html

Jamie Thomson UCSB photo

“During 2011 and 2012, we had three
large biopharmaceutical customers that individually accounted for
greater than 10% of our total revenue in one or both years. Eli Lilly
and Company (Lilly) accounted for 10% of total revenue in 2011 and
18% of total revenue in 2012. Hoffmann-La Roche Inc. (Roche)
accounted for 13% of total revenue in 2011 and GlaxoSmithKline plc
(GSK) accounted for 11% of our total revenue in 2012.”

“Our total revenue grew from $2.6
million in 2011 to $6.6 million in 2012, an increase of 154%. This
growth was driven by a 247% increase in sales of our iCell products
which grew from $1.5 million in 2011 to $5.2 million in 2012. At
December 31, 2011, our backlog of revenue expected to be recognized
in 2012 was $1.1 million. At December 31, 2012, our backlog of
revenue expected to be recognized in 2013 had grown to $4.1 million.

“For the three months ended March 31,
2013 our total revenue was $2.4 million, an increase of 109% over the
corresponding period in 2012. This growth was driven primarily by an
increase in iCell product sales, which grew from $0.6 million for the
three months ended March 31, 2012 to $1.8 million for the three
months ended March 31, 2013, an increase of 173%.”

"A
recent question is the issue of who has the intellectual property
(IP) rights to iPS cell technology. People have told me in the
past that they wondered if Cellular Dynamics has unambiguous rights
to develop all of these iPS cell-based products."

 “This (the IPO) looks to
be very interesting and could transform the field as it develops.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0oup8hU2FGE/cellular-dynamics-california-stem-cell.html

“It can’t help but increase the
value of other stem cell companies.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iGlLbdQVr0Y/light-coverage-of-cellular-dynamics-ipo.html

Claire Pomeroy CIRM photo

“For some children, the uncertainty
of life on the street is better than certainty of violence at home.
It was for me. At age 14, I escaped from an abusive home with no
money, nowhere to go and only the clothes I was wearing. I remember
staring into the night, standing somewhere between fear and freedom.
I became one of the millions of homeless teens, yet I was lucky
because foster care ultimately saved me.”

“However, after an emergency
placement and three foster homes, the challenges were not over. At 17
I aged out of the foster care system early when my foster parents
moved out of state. On my own again, I had to find a job, a place to
live and finish high school. Then I climbed the next mountain to
graduate from college and medical school.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zancriHTUC4/pomeroy-on-doing-right-thing-and-foster.html

Jamie Thomson UCSB photo

“During 2011 and 2012, we had three
large biopharmaceutical customers that individually accounted for
greater than 10% of our total revenue in one or both years. Eli Lilly
and Company (Lilly) accounted for 10% of total revenue in 2011 and
18% of total revenue in 2012. Hoffmann-La Roche Inc. (Roche)
accounted for 13% of total revenue in 2011 and GlaxoSmithKline plc
(GSK) accounted for 11% of our total revenue in 2012.”

“Our total revenue grew from $2.6
million in 2011 to $6.6 million in 2012, an increase of 154%. This
growth was driven by a 247% increase in sales of our iCell products
which grew from $1.5 million in 2011 to $5.2 million in 2012. At
December 31, 2011, our backlog of revenue expected to be recognized
in 2012 was $1.1 million. At December 31, 2012, our backlog of
revenue expected to be recognized in 2013 had grown to $4.1 million.

“For the three months ended March 31,
2013 our total revenue was $2.4 million, an increase of 109% over the
corresponding period in 2012. This growth was driven primarily by an
increase in iCell product sales, which grew from $0.6 million for the
three months ended March 31, 2012 to $1.8 million for the three
months ended March 31, 2013, an increase of 173%.”

"A
recent question is the issue of who has the intellectual property
(IP) rights to iPS cell technology. People have told me in the
past that they wondered if Cellular Dynamics has unambiguous rights
to develop all of these iPS cell-based products."

 “This (the IPO) looks to
be very interesting and could transform the field as it develops.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0oup8hU2FGE/cellular-dynamics-california-stem-cell.html

“It can’t help but increase the
value of other stem cell companies.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iGlLbdQVr0Y/light-coverage-of-cellular-dynamics-ipo.html

Claire Pomeroy CIRM photo

“For some children, the uncertainty
of life on the street is better than certainty of violence at home.
It was for me. At age 14, I escaped from an abusive home with no
money, nowhere to go and only the clothes I was wearing. I remember
staring into the night, standing somewhere between fear and freedom.
I became one of the millions of homeless teens, yet I was lucky
because foster care ultimately saved me.”

“However, after an emergency
placement and three foster homes, the challenges were not over. At 17
I aged out of the foster care system early when my foster parents
moved out of state. On my own again, I had to find a job, a place to
live and finish high school. Then I climbed the next mountain to
graduate from college and medical school.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zancriHTUC4/pomeroy-on-doing-right-thing-and-foster.html

Sugar 1week post stem cell therapy

By: Tim O #39;Neill, DVM

The rest is here:
Sugar 1week post stem cell therapy - Video

Streak #39;s Before/After Stemlogix Stem Cell Therapy
Check out Streak #39;s amazing Post Stemlogix Stem Cell Therapy progression video from day 1 to day 37 ! The day of the stem cell therapy Streak could barely wal...

By: Stemlogix, LLC

Visit link:
Streak's Before/After Stemlogix Stem Cell Therapy - Video

Stem Cell Therapy- Victoria Hicks

By: Victoria Hicks

Read more:
Stem Cell Therapy- Victoria Hicks - Video